Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...

II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 13, 2025 (GLOBE NEWSWIRE) -- Paris, ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Detailed price information for Virtus Lifesci Biotech Clinical Trials ETF (BBC-A) from The Globe and Mail including charting and trades.

Fintel reports that on February 24, 2025, LifeSci Capital initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform recommendation. As of February 19, 2025, the average one-year price ...